arrow
H

Hatem Soliman

university of texas system
H指数:45
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Breast Cancer, Version 5.2025 Featured Updates to the NCCN Guidelines

Gradishar, W.J.; Moran, M.S.; Abraham, J.; Abranson, V.; Aft, R.; Agnese, D.; Allison, K.H.; Anderson, B.; Bailey, J.; Burstein, H.J.; et al. NCCN指南,乳腺癌,版本5。J. Natl. Compr. Cancer Netw. 2025, 23, 426–436. [Google Scholar] [CrossRef]

2025-11-013
PRE
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report

Sacituzumab govitecan和立体定向放射手术治疗HER2阴性乳腺癌脑转移瘤:一项多中心报告

2025-09-300
PRE
Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER2S study

设计一项集群随机多水平干预,以减少少数民族癌症患者转诊和入组癌症临床试验的障碍:ACT WONDER2S研究

2025-09-011
OAAI
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study

Nivolumab和立体定向放射外科治疗乳腺癌脑转移患者:一项非随机、开放标签、Ib期研究的长期结果和生物标志物分析

2025-04-280
OA
Phase II trial of brain MRI surveillance in stage IV breast cancer

IV期乳腺癌中脑MRI监测的II期临床试验

2025-01-240
PRE
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases
2024-11-211
OA
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy

接受新辅助化免疫治疗的早期乳腺癌患者乳腺MRI上区域淋巴结的改变

2024-09-210
OAAI
First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors

首次人体I期试验:评估溶瘤单纯疱疹病毒ONCR-177单药或联合帕博利珠单抗治疗晚期实体瘤的效果

2024-09-010
PRE
Breast Cancer, Version 3.2024
2024-07-0120
PRE
Phase 2 Study of Preoperative SABR for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiation Therapy
2023-07-012
PRE
Breast Cancer, Version 4.2023
2023-06-01149
OA
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial (vol 29, 450, 2023)
2023-03-171
OA
PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)
2022-11-070
OA